1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
63A38A7F8A90C11F185256C63005B7EB5
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/early-stage-product-commercialization-improve-decision-making-enhance-product-design?opendocument
18
19opendocument
203.80.4.76
21
22
23
24/bestp/domrep.nsf
25DB




Products & Services New Product Development Early stage commercialization

Early Stage Product Commercialization: Summary and Lessons Learned

DB Image

ID: 4312


Features:

Graphics


Words: 4,608


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Since the percentage of successful compounds is so small and the development cycle so long, leading pharmaceutical companies strive to allocate resources to compounds with the greatest potential market value, and they begin investing marketing dollars in those drugs early in the development process. The challenge before leading global pharmaceutical companies is to accelerate the evolution from ad-hoc early-stage product commercialization to an integrated function that brings ongoing market insights to the new-product development and portfolio management process. Companies that effectively develop this organizational capability to improve early-stage decision-making and enhance product design using commercial insights will gain an overall competitive advantage in the marketplace. This 17-page document discusses key findings from benchmarking research with 11 leading companies--10 of them in the pharmaceutical industry. The document also includes a section on top lessons learned in early-stage commercialization at each of the benchmarked companies.

Industries Profiled:
Biotech; Health Care; Pharmaceutical; Diagnostic; Manufacturing; Consumer Products; Medical Device; Automobile


Companies Profiled:
Allergan; Abbott; Bayer; Bristol-Myers Squibb; Boehringer-Ingelheim; Eli Lilly and Company; GlaxoSmithKline; General Motors; Johnson & Johnson; Novartis; Pfizer

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.